search
Back to results

CVD Risk and Health in Postmenopausal Phytoestrogen Users

Primary Purpose

Bone Diseases, Cardiovascular Diseases, Coronary Disease

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
dietary supplements
genistein
diet, soy proteins
Sponsored by
National Heart, Lung, and Blood Institute (NHLBI)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for Bone Diseases

Eligibility Criteria

45 Years - 74 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Postmenopausal women, ages 45 to 74.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    October 27, 1999
    Last Updated
    February 26, 2016
    Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00000613
    Brief Title
    CVD Risk and Health in Postmenopausal Phytoestrogen Users
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2005
    Overall Recruitment Status
    Completed
    Study Start Date
    April 1997 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    December 2004 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Heart, Lung, and Blood Institute (NHLBI)

    4. Oversight

    5. Study Description

    Brief Summary
    To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.
    Detailed Description
    BACKGROUND: Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of life in postmenopausal women through use of a dietary supplement of phytoestrogen. DESIGN NARRATIVE: Randomized, double-blind, placebo-controlled study. A total of 210 women were enrolled in the study to be followed for one to two years. The women were randomized to phytoestrogen treatment or to placebo. Data are collected at baseline visits, at one and three month follow-up telephone calls, and at 6, 12, and 24 month follow-up clinic visits. Measures of high density lipoprotein and other heart disease risk factors, hip and spine bone density, and depression, life satisfaction, and quality of well-being are obtained. Cross-sectional and longitudinal comparisons of treatment and placebo groups are performed before and after adjustment and stratification for potentially confounding covariates. The study was renewed in March 2002 to assess whether the women treated with phytoestrogens had lowered homocysteine, interleukin-6, C-reactive protein, E-selectin, and decreased obesity and fat mass over two years. The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Bone Diseases, Cardiovascular Diseases, Coronary Disease, Depression, Heart Diseases, Myocardial Ischemia, Osteoporosis, Postmenopause

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 2
    Masking
    Double
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Behavioral
    Intervention Name(s)
    dietary supplements
    Intervention Type
    Drug
    Intervention Name(s)
    genistein
    Intervention Type
    Behavioral
    Intervention Name(s)
    diet, soy proteins

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    45 Years
    Maximum Age & Unit of Time
    74 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Postmenopausal women, ages 45 to 74.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Donna Kritz-Silverstein
    Organizational Affiliation
    University of California, San Diego

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    11285326
    Citation
    Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J Nutr. 2001 Apr;131(4):1202-6. doi: 10.1093/jn/131.4.1202.
    Results Reference
    background
    PubMed Identifier
    11860727
    Citation
    Kritz-Silverstein D, Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women. J Womens Health Gend Based Med. 2002 Jan-Feb;11(1):69-78. doi: 10.1089/152460902753473480.
    Results Reference
    background
    PubMed Identifier
    14501604
    Citation
    Goodman-Gruen D, Kritz-Silverstein D. Usual dietary isoflavone intake and body composition in postmenopausal women. Menopause. 2003 Sep-Oct;10(5):427-32. doi: 10.1097/01.GME.0000058866.35869.B4.
    Results Reference
    background

    Learn more about this trial

    CVD Risk and Health in Postmenopausal Phytoestrogen Users

    We'll reach out to this number within 24 hrs